264 related articles for article (PubMed ID: 35933091)
1. KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy.
Li Y; Lv C; Yu Y; Wu B; Zhang Y; Lang Q; Liang Z; Zhong C; Shi Y; Han S; Xu F; Tian Y
J Adv Res; 2023 May; 47():137-150. PubMed ID: 35933091
[TBL] [Abstract][Full Text] [Related]
2. HHLA2 immune-regulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jun; 162():114639. PubMed ID: 37011487
[TBL] [Abstract][Full Text] [Related]
3. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target.
Wei Y; Ren X; Galbo PM; Moerdler S; Wang H; Sica RA; Etemad-Gilbertson B; Shi L; Zhu L; Tang X; Lin Q; Peng M; Guan F; Zheng D; Chinai JM; Zang X
Sci Immunol; 2021 Jul; 6(61):. PubMed ID: 34244312
[TBL] [Abstract][Full Text] [Related]
4. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.
Bhatt RS; Berjis A; Konge JC; Mahoney KM; Klee AN; Freeman SS; Chen CH; Jegede OA; Catalano PJ; Pignon JC; Sticco-Ivins M; Zhu B; Hua P; Soden J; Zhu J; McDermott DF; Arulanandam AR; Signoretti S; Freeman GJ
Cancer Immunol Res; 2021 Feb; 9(2):156-169. PubMed ID: 33229411
[TBL] [Abstract][Full Text] [Related]
5. Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies.
Pulanco MC; Madsen AT; Tanwar A; Corrigan DT; Zang X
Cell Mol Immunol; 2023 Jul; 20(7):694-713. PubMed ID: 37069229
[TBL] [Abstract][Full Text] [Related]
6. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
[TBL] [Abstract][Full Text] [Related]
7. Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy.
Ying H; Xu J; Zhang X; Liang T; Bai X
EBioMedicine; 2022 May; 79():103987. PubMed ID: 35439678
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer.
Zhang D; Xie J; Sun F; Xu R; Liu W; Xu J; Huang X; Zhang G
Cancer Lett; 2024 May; 589():216819. PubMed ID: 38522775
[TBL] [Abstract][Full Text] [Related]
9. The Expression Patterns and Associated Clinical Parameters of Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 and Transmembrane and Immunoglobulin Domain Containing 2 in Oral Squamous Cell Carcinoma.
Xiao Y; Li H; Yang LL; Mao L; Wu CC; Zhang WF; Sun ZJ
Dis Markers; 2019; 2019():5421985. PubMed ID: 31089395
[TBL] [Abstract][Full Text] [Related]
10. HHLA2 Activates the JAK/STAT Signaling Pathway by Binding to TMIGD2 in Hepatocellular Carcinoma Cells.
Guo H; Zhang C; Tang X; Zhang T; Liu Y; Yu H; Li Y; Wang R
Inflammation; 2022 Aug; 45(4):1585-1599. PubMed ID: 35175496
[TBL] [Abstract][Full Text] [Related]
11. HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families.
Janakiram M; Chinai JM; Zhao A; Sparano JA; Zang X
Oncoimmunology; 2015 Aug; 4(8):e1026534. PubMed ID: 26405587
[TBL] [Abstract][Full Text] [Related]
12. A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2.
Xiao Y; Freeman GJ
Clin Cancer Res; 2015 May; 21(10):2201-3. PubMed ID: 25869386
[TBL] [Abstract][Full Text] [Related]
13. Overexpression and Role of HHLA2, a Novel Immune Checkpoint, in Colorectal Cancer.
Kula A; Dawidowicz M; Mielcarska S; Kiczmer P; Skiba H; Krygier M; Chrabańska M; Piecuch J; Szrot M; Robotycka J; Ochman B; Strzałkowska B; Czuba Z; Świętochowska E; Waniczek D
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982953
[TBL] [Abstract][Full Text] [Related]
14. Mystery Checkpoint Revealed: KIR3DL3 Finally Found a Ligand in HHLA2.
Campbell KS
Cancer Immunol Res; 2021 Feb; 9(2):128. PubMed ID: 33536266
[TBL] [Abstract][Full Text] [Related]
15. The B7:CD28 family and friends: Unraveling coinhibitory interactions.
Burke KP; Chaudhri A; Freeman GJ; Sharpe AH
Immunity; 2024 Feb; 57(2):223-244. PubMed ID: 38354702
[TBL] [Abstract][Full Text] [Related]
16. B7-H7: A potential target for cancer immunotherapy.
Su Q; Du J; Xiong X; Xie X; Wang L
Int Immunopharmacol; 2023 Aug; 121():110403. PubMed ID: 37290327
[TBL] [Abstract][Full Text] [Related]
17. Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells.
Palmer WH; Leaton LA; Campos Codo A; Crute B; Roest J; Zhu S; Petersen J; Tobin RP; Hume PS; Stone M; van Bokhoven A; Gerich ME; McCarter MD; Zhu Y; Janssen WJ; Vivian JP; Trowsdale J; Getahun A; Rossjohn J; Cambier J; Loh L; Norman PJ
Sci Immunol; 2023 Jun; 8(84):eade5343. PubMed ID: 37390222
[TBL] [Abstract][Full Text] [Related]
18. B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling.
Rieder SA; Wang J; White N; Qadri A; Menard C; Stephens G; Karnell JL; Rudd CE; Kolbeck R
Cell Mol Immunol; 2021 Jun; 18(6):1503-1511. PubMed ID: 32005952
[TBL] [Abstract][Full Text] [Related]
19. Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein.
Janakiram M; Chinai JM; Fineberg S; Fiser A; Montagna C; Medavarapu R; Castano E; Jeon H; Ohaegbulam KC; Zhao R; Zhao A; Almo SC; Sparano JA; Zang X
Clin Cancer Res; 2015 May; 21(10):2359-66. PubMed ID: 25549724
[TBL] [Abstract][Full Text] [Related]
20. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
Huang FX; Wu JW; Cheng XQ; Wang JH; Wen XZ; Li JJ; Zhang Q; Jiang H; Ding QY; Zhu XF; Zhang XS; Ding Y; Li DD
Front Immunol; 2022; 13():902167. PubMed ID: 36003385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]